skg0106
Gene therapyexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 5, 2023 (NCT06213038)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Molecular identity unknownSupplementation
Molecular identity unknown supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06237777 | Phase 1 | May 31, 2024 | Fudan University |
| NCT05986864 | Phase 1/Phase 2 (Phase 2) | Oct 30, 2023 | Skyline Biosciences |
| NCT06213038 | Phase 1 | May 5, 2023 | Chinese Academy of Medical Sciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Skyline Biosciences | For profit | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1